10-Q: Electromed Q1 Revenue Jumps 15% on Strong Sales Growth

Electromed, Inc. reported a 15.1% increase in net revenues and a 44.9% rise in net income for the first fiscal quarter ended September 30, 2025, driven by robust homecare and hospital sales.

Summary

• Net revenues for the three months ended September 30, 2025, increased by 15.1% to $16,887,000, up from $14,668,000 in the prior year.
• Net income for the quarter rose by 44.9% to $2,136,000, compared to $1,474,000 in the same period last year.
• Basic earnings per share increased to $0.26 from $0.17, and diluted earnings per share increased to $0.25 from $0.16.
• Operating income grew by 37.8% to $2,670,000, up from $1,938,000 in the prior year.
• The company initiated a stock repurchase program on September 9, 2025, authorizing up to $10,000,000, and has repurchased 40,848 shares for $1,003,000 as of September 30, 2025.
• Cash and cash equivalents decreased by $1,174,000 during the quarter, ending at $14,113,000.
• Net cash provided by operating activities significantly decreased to $169,000 from $2,309,000 in the prior year, primarily due to changes in working capital items like accrued compensation and inventories.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant increases in revenue, net income, and operating income. The initiation of a share repurchase program is a positive signal to shareholders. While cash from operations decreased, the overall financial health and growth trajectory are robust.

Positives

• Net revenues increased by 15.1% to $16,887,000, demonstrating strong top-line growth.
• Net income surged by 44.9% to $2,136,000, indicating improved profitability.
• Operating income increased by 37.8% to $2,670,000, reflecting efficient operations.
• Homecare revenue grew by 12.7% to $14,889,000, driven by an increase in direct sales representatives and higher net revenues per representative.
• Hospital revenue saw a substantial increase of 51.7% to $1,047,000, attributed to more sales representatives focused on this market and higher demand.
• Homecare distributor revenue increased by 41.2% to $829,000, due to an increased number of distribution partners.
• The company authorized a $10,000,000 stock repurchase program, signaling confidence in its valuation and a commitment to shareholder returns.
• The effective tax rate decreased to 23.8% from 30.9% in the prior year, partially due to a discrete tax benefit.

Negatives

• Net cash provided by operating activities decreased significantly to $169,000 from $2,309,000 in the prior year, primarily due to a $2,348,000 decrease in accrued compensation and increases in inventories and prepaid expenses.
• Gross profit percentage slightly decreased to 78.1% from 78.3%, a result of higher costs partially offset by higher net revenues per device.
• Interest income, net, decreased to $134,000 from $195,000, primarily due to decreased interest rates and cash balances.
• Other revenue decreased by 32.2% to $122,000, mainly due to lower demand from international distributors and other customers.

Risks

• Ability to obtain and maintain reimbursement from Medicare, Medicaid, or private insurance payers for products.
• Component or raw material shortages, changes to lead times, significant price increases, and changes to trade regulations (including tariffs).
• Adverse changes to state and federal health care regulations.
• Ability to maintain regulatory compliance and to gain future regulatory approvals and clearances.
• Entry of new competitors, including new drug or pharmaceutical discoveries.
• Adverse economic and business conditions or intense competition.
• Wage inflation affecting operational costs.
• Technical problems with research and products.
• Risks associated with cyberattacks, data breaches, computer viruses, and other similar security threats.
• Changes affecting the medical device industry.
• Ability to develop new sales channels for products such as the hospital or homecare distributor channels.
• Adverse international health care regulation impacting current international business.
• Ability to renew the existing line of credit or obtain additional credit as necessary.
• Ability to protect and expand the intellectual property portfolio.

Future Outlook

The company anticipates continued investment in research and development and marketing activities, expecting sustained earnings, gross margins, and sales growth across its homecare, hospital, and international sales channels. Management believes its products will continue to qualify for reimbursement under government and private insurance programs. The company expects its current working capital and credit facility to provide sufficient liquidity for the next twelve months and is evaluating the impact of new accounting standards and the One Big Beautiful Bill Act on future financial reporting and tax payments.

Management Comments

• The increase in homecare revenue was primarily due to an increase in direct sales representatives and higher net revenues per sales representative.
• Hospital revenue growth primarily reflects an increase in sales representatives focused on the hospital market and higher capital and disposal demand.
• The increase in homecare distributor sales was primarily a result of an increased number of distribution partners.
• The increase in SG&A expenses was primarily due to the increase in salaries and incentive compensation related to the higher average number of sales, marketing, and reimbursement personnel to process higher patient referrals, as well as increased travel and marketing investments.
• The increase in R&D expenses was primarily due to increased average headcount and external spend related to product enhancements and sustaining engineering.
• Our working capital of approximately $35,800,000 and available borrowings under our existing credit facility will provide sufficient liquidity to meet our anticipated working capital and other liquidity needs for the next twelve months.

Industry Context

Electromed operates in the specialized medical device sector, focusing on High Frequency Chest Wall Oscillation (HFCWO) therapy for chronic pulmonary conditions. The strong revenue growth, particularly in homecare and hospital segments, suggests successful market penetration and potentially increasing demand for HFCWO devices. The company's strategy of expanding its direct sales force and distribution partners aligns with efforts to capture a larger share of the market for conditions like bronchiectasis and cystic fibrosis. The emphasis on reimbursement eligibility highlights the critical role of healthcare policy and payer relations in this industry.

Stakeholder Impact

• Shareholders: Benefit from increased net income, higher EPS, and the ongoing share repurchase program, which can enhance shareholder value.
• Employees: Benefit from increased payroll and compensation-related expenses, including merit-based increases and share-based compensation, reflecting investment in talent.
• Customers: Benefit from continued product enhancements and sustaining engineering efforts, as indicated by increased R&D spending.
• Creditors: The company maintains a healthy working capital and no outstanding balance on its credit facility, indicating strong financial stability for creditors.

Next Steps

• Evaluate the impact of ASU 2023-09 (Income Taxes) for adoption in fiscal year ending June 30, 2026.
• Evaluate the impact of ASU 2024-03 (Expense Disaggregation Disclosures) for adoption in fiscal year ending June 30, 2028.
• Evaluate the recognition of deferred tax assets and acceleration options related to the One Big Beautiful Bill Act (OBBBA).
• Potentially renew or replace the existing $2,500,000 revolving line of credit before its expiration on December 18, 2025.
• Continue to execute the $10,000,000 share repurchase program, with approximately $8,997,000 remaining.

Key Dates

Recommendation

Electromed, Inc. delivered a strong first fiscal quarter, marked by significant revenue growth across all key segments (homecare, hospital, and homecare distributor) and a substantial increase in net income. The company's strategic investments in its sales force and market development are yielding positive results. The initiation of a $10 million share repurchase program underscores management's confidence in the company's valuation and commitment to returning capital to shareholders. While operating cash flow saw a temporary dip due to working capital adjustments, the underlying operational performance and profitability are robust, suggesting continued positive momentum for the stock.

Keywords

Electromed, ELMD, airway clearance, HFCWO, SmartVest, medical device, pulmonary care, bronchiectasis, cystic fibrosis, quarterly results, revenue growth, net income, stock repurchase